Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
Nashville, Tennessee, 37212-2637, United States
NCT Number: NCT06089057
This is a pilot trial of a 16-week physical activity and power training program among up to 30 Veterans/arm with advanced chronic kidney disease. The trial aims to test whether the program is tolerable to Veterans.
Interested in participating?
Request InfoAll sexes
Interventional
Not applicable
Nashville, Tennessee, 37212-2637, United States
This will be a randomized controlled pilot trial of a 16-week physical activity and power training intervention trial among up to 30 pre-frail Veterans with Stage 3B-5 chronic kidney disease. The intervention will contain in-center and at-home components. It will lay the foundation for a large-scale future randomized controlled efficacy trial aimed to reduce frailty risk among Veterans with advanced chronic kidney disease. Up to 30 other Veterans will be part of an attention control.
The outcomes of this pilot trial are feasibility, acceptability, and fidelity. Each of these outcomes will be measured using quantitative surveys and data review as well as qualitative assessments among Veterans at trial close. As this is a pilot feasibility trial, it is intentionally not powered to detect whether the intervention has a significant effect on physical activity frequency, muscle strength, or physical frailty.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This is a 16-week power-training and physical activity-focused intervention that contains group in-center and individual at-home components and motivational coaching. Participants will meet 2-3 times per week for the in-center power training. Participants will also be asked to wear accelerometers at home in order for their physical activity frequency to be measured.
Other names: PACT to AGE WELL with CKD
This will be the attention control arm that will involve receipt of a physical activity education booklet, use of an accelerometer, and weekly check-in calls. No power training or motivational coaching will be delivered.
Other names: Attention Control for PACT to AGE WELL with CKD
Time frame: 4 months
This will be a brief questionnaire known as the Feasibility of Intervention Measure, that asks participants whether the intervention seems doable to them. There are four questions, and participants are asked to rate intervention feasibility from a scale of 1 (Strongly Disagree) to 5 (Strongly Agree). Scores range from 1-5 and are calculated as the mean of all scores. Higher scores indicate greater perceived feasibility. This will not be aggregated with any other measure.
Time frame: 4 months
This will be a numeric percentage of participants who consent for the pilot trial out of all eligible participants in Aim 1. This will not be aggregated with any other measure.
Time frame: 4 months
This will be a qualitative description of potential participants' reasons for declining, if applicable. This will not be aggregated with any other measure.
Time frame: 4 months
This will be a brief questionnaire known as the Acceptability of Intervention Measure, that asks participants whether the intervention seems acceptable and/or enjoyable to them. There are four questions, and participants are asked to rate intervention acceptability from a scale of 1 (Strongly Disagree) to 5 (Strongly Agree). Scores range from 1-5 and are calculated as the mean of all scores. Higher scores indicate greater perceived acceptability. This will not be aggregated with any other measure.
Time frame: 4 months
This will be a qualitative description of participants' reasons they found the intervention enjoyable to participate in, if applicable. This will not be aggregated with any other measure.
Time frame: 4 months
This will be a percentage, measured by the number of sessions a participant attended out of all possible sessions that could have have been attended. This will not be aggregated with any other measure.
Time frame: 5 months, 6 months, and 7 months
This will be the step count during the prior week recorded on an accelerometer worn by each participant. This will be measured at each of the following time points: one, two, and three months after intervention close. That is to say, this will be measured at 5 months, 6 months, and 7 months after intervention start. This will not be aggregated with any other measure.
Time frame: 5 months, 6 months, and 7 months
This will be measured using the questionnaire, the Physical Activity Scale for the Elderly, a ten-item questionnaire that inquires about the frequency, duration, and intensity of physical activity during the prior week. Scores range from 0-793, with higher scores indicating completion of more frequent and/or intense physical activity. This will be measured at each of the following time points: one, two, and three months after intervention close. That is to say, this will be measured at 5 months, 6 months, and 7 months after intervention start. This will not be aggregated with any other measure.
Time frame: 7 months
This will be a qualitative description of participants' reasons for adhering to the intervention or not, as applicable. This will not be aggregated with any other measure.
Time frame: 7 months
This will be the total number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 5.0. This will not be aggregated with any other measure.
Time frame: 7 months
This will be the type of adverse events as reported by participants from the Common Terminology Criteria for Adverse Events version 5.0. This will not be aggregated with any other measure.
VA Office of Research and Development
Fed
Activation for Self-Care Needs in Older Adults With Chronic Kidney Disease: ACTIVE SENIORS With CKD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06998563
Femoral Anteversion, Functional Capacity
Istanbul, Turkey (Türkiye)
View Trial Details